Thera-SAbDab

LIRENTELIMAB

>   Structural Summary
TherapeuticLirentelimab
TargetSIGLEC8/SAF2
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFSLTIYGAHWVRQAPGKGLEWVGVIWAGGSTNYNSALMSRFTISKDNSKNTVYLQMNSLRAEDTAVYYCARDGSSPYYYSMEYWGQGTTVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCSATSSVSYMHWFQQKPGQAPRLLIYSTSNLASGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSSYPFTFGPGTKLDIK
100% seqID Fv StructureNone
99% seqID Fv Structure7quh [Fvs: HL]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Lirentelimab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 99.56%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 101 102 103 104 105 106 107 108 109 110 111 112 113
lirentelimab E V Q L V E S G G G L V Q P G G S L R L S C A A S G F S L T I Y G A H W V R Q A P G K G L E W V G V I W A G G S T N Y N S A L M S R F T I S K D N S K N T V Y L Q M N S L R A E D T A V Y Y C A R D G S S P Y Y Y S M E Y W G Q G T T V T V S S
7quh E V Q L V E S G G G L V Q P G G S L R L S C A A S G F S L T I Y G A H W V R Q A P G K G L E W V S V I W A G G S T N Y N S A L M S R F T I S K D N S K N T V Y L Q M N S L R A E D T A V Y Y C A R D G S S P Y Y Y S M E Y W G Q G T T V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
lirentelimab E I V L T Q S P A T L S L S P G E R A T L S C S A T S S V S Y M H W F Q Q K P G Q A P R L L I Y S T S N L A S G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q R S S Y P F T F G P G T K L D I K
7quh E I V L T Q S P A T L S L S P G E R A T L S C S A T S S V S Y M H W F Q Q K P G Q A P R L L I Y S T S N L A S G I P A R F S G S G S G T D F T L T I S S L E P E D F A V Y Y C Q Q R S S Y P F T F G P G T K L D I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Phase-III
Estimated Status (August '23)Active
Recorded Developmental Technology
INN Year Proposed2020
INN Year Recommended2021
Companies InvolvedAllakos
Conditions Approvedna
Conditions ActiveEosinophilic gastroenteritis, Eosinophilic oesophagitis, Urticari, Atopic dermatitis, Chronic obstructive pulmonary disease
Conditions DiscontinuedConjunctiviti, Fibrosis, Kertoconjunctivitis, Systemic mastocytosis
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy